A review on thyroid cancer during pregnancy: Multitasking is required

Khaled, Hussein M.; Lahloubi, Nasr Al; Rashad, Noha

doi:10.1016/j.jare.2016.02.007

Cited by 37 publications

(50 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…4,11 This is in contrast to some observations regarding thyroid cancer and pregnancy, in which an association was noted in the near term, but dissipated over time. 14,15 It may be due to the different pathophysiologies in both conditions.…”

Section: Discussionmentioning

confidence: 99%

“…The increasing trend of infertility in women is a rising concern and has attracted attention. Thoma et al used a current duration approach to estimate that the prevalence of infertility could be as high as 15.5% in the United States. 1 The use of artificial reproductive technology also has become an increasing concern with regard to the subsequent risk of cancer.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Thyroid cancer risk in women with infertility and association with fertility medications in Taiwan

Ding

Chen

Wang

et al. 2019

Cancer

View full text Add to dashboard Cite

Background The current study evaluated whether the risk of developing thyroid cancer in Asian women was associated with infertility and the use of fertility drugs. Methods The authors conducted a large, retrospective cohort study using Taiwan's National Health Insurance Research Database. From the insurance claims data, a total of 13,356 women aged 20 to 49 years who were diagnosed with infertility from 2000 through 2013 were included in the infertile group, and 53,424 women without a history of infertility were selected as fertile comparisons and were frequency matched by age and year of diagnosis. Both groups were followed up to 2013 to calculate incident thyroid cancer. Poisson regression analysis was used to estimate the incidence rate ratio (IRR). Results The incidence of thyroid cancer was 1.9‐fold greater in the infertile group compared with the comparison group (2.85 vs 1.53 per 10,000 person‐years), with an adjusted IRR of 1.80 (95% confidence interval [95% CI], 1.70‐1.92) for the infertile group. Higher cancer incidence was demonstrated for the infertile group after 7 years of follow‐up, with an adjusted IRR of 4.39 (95% CI, 4.03‐4.78) compared with the comparison group. Among infertile women, those who had taken the fertility drug clomiphene were found to have a reduced incidence of thyroid cancer compared with those who were treated without the drug (2.69 vs 3.42 per 10,000 person‐years), with an adjusted IRR of 0.86 (95% CI, 0.75‐0.99). However, the cancer incidence in infertile women being treated with clomiphene was nearly 6‐fold greater than that in fertile women taking the drug. Conclusions The results of the current study provide evidence that women with infertility are at an increased risk of developing thyroid cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Thyroid cancer risk in women with infertility and association with fertility medications in Taiwan

Ding

Chen

Wang

et al. 2019

Cancer

View full text Add to dashboard Cite

show abstract

“…Of all 29 patients who had surgery during pregnancy, 20 had WDTC (T<3N0), and postponement of surgery until after delivery would have been an option based on the current general consensus. Nonobstetrical surgery in pregnant patients has, however, been described to be safe in all trimesters, and pregnant women with cancer should be treated as nonpregnant cancer patients when possible . Furthermore, delaying primary treatment until after delivery can cause an extra psychological burden and stress for the mother, especially when diagnosed in the first trimester and the time between diagnosis and treatment is substantial.…”

Section: Discussionmentioning

confidence: 99%

“…18,36 Alternatively, second trimester total thyroidectomy is advised. 18,36 The majority of patients underwent surgical therapy during pregnancy (n 5 29, 83%). Most of them were diagnosed in the first (n 5 12) or second (n 5 14) trimester.…”

Section: Treatmentmentioning

confidence: 99%

Maternal and obstetrical outcome in 35 cases of well‐differentiated thyroid carcinoma during pregnancy

et al. 2017

View full text Add to dashboard Cite

show abstract

“…However, the expression of these genes in which promoter methylation is detected in 30% of thyroid tumor was commonly downregulated in thyroid cancer patients 40,41. In addition, the hypermethylation of thyrotropin receptor gene, receptor, fibroblast growth factor type 2, and receptor, fibroblast growth factor type 1 existed in thyroid cancers 42–44. RASSF1A protein, lacking enzymatic activity, contains a Ras-association domain and can regulate the cell cycle and apoptosis 13,14.…”

Section: Discussionmentioning

confidence: 99%

RASSF1A promoter methylation is associated with increased risk of thyroid cancer: a meta-analysis

Shou¹,

Xu²,

Li³

et al. 2017

OTT

View full text Add to dashboard Cite

ObjectivePrevious studies have reported that Ras-associated domain family 1A (RASSF1A), the most commonly silenced tumor suppressor via promoter methylation, played vital roles in the development of carcinogenesis. The purpose of this meta-analysis was to determine whether RASSF1A promoter methylation increased the risk of thyroid cancer.MethodsPubMed, Embase, ISI Web of Knowledge, and Chinese National Knowledge Infrastructure databases were searched to obtain eligible studies. The pooled odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to estimate the strength of the associations, using Stata 12.0 software. The methodological quality of included studies was evaluated using Newcastle–Ottawa scale table. Egger’s test and Begg’s test were applied to detect publication biases. TSA 0.9 software was used to calculate the required information size and whether the result was conclusive.ResultsA total of 10 articles with 12 studies that included 422 thyroid cancer patients, identifying the association of RASSF1A promoter methylation with thyroid cancer risk, were collected in this meta-analysis. Overall, RASSF1A promoter methylation significantly increased the risk of thyroid cancer (total, OR=8.27, CI=4.38–15.62, P<0.05; Caucasian, OR=9.25, CI=3.97–21.56, P<0.05; Asian, OR=7.01, CI=2.68–18.38, P<0.05). In the subgroup analysis based on sample type, a significant association between thyroid cancer group and control group was found (normal tissue, OR=9.55, CI=4.21–21.67, P<0.05; adjacent tissue, OR=6.80, CI=2.49–18.56, P<0.05). The frequency of RASSF1A promoter methylation in follicular thyroid carcinoma was higher than in control group (OR=11.88, CI=5.80–24.32, P<0.05). In addition, the results indicated that the RASSF1A promoter methylation was correlated with papillary thyroid carcinoma in Caucasians and Asians (total, OR=8.07, CI=3.54–18.41, P<0.05; Caucasian, OR=11.35, CI=2.39–53.98, P<0.05; Asian, OR=6.67, CI=2.53–17.64, P<0.05). On the basis of the trial sequential analysis, the significant association of RASSF1A promoter methylation with thyroid cancer risk was found, and there was no need to perform further studies.ConclusionThis meta-analysis confirms that RASSF1A promoter methylation is a risk factor for thyroid tumor.

show abstract

A review on thyroid cancer during pregnancy: Multitasking is required

Abstract: Graphical abstract

Cited by 37 publications

References 38 publications

Thyroid cancer risk in women with infertility and association with fertility medications in Taiwan

Thyroid cancer risk in women with infertility and association with fertility medications in Taiwan

Maternal and obstetrical outcome in 35 cases of well‐differentiated thyroid carcinoma during pregnancy

RASSF1A promoter methylation is associated with increased risk of thyroid cancer: a meta-analysis

Contact Info

Product

Resources

About